Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07438496 · ClinicalTrials.gov registry record · Phase 3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
A Phase 3 study of Lupus Erythematosus, Systemic, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 5
- Study locations
NCT07438496 is a Phase 3 study of Lupus Erythematosus, Systemic that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 600 participants, above the 183-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (228% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT07438496, a Phase 3 study of Lupus Erythematosus, Systemic, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nipocalimab
- DRUG Standard of care treatment
Study Locations (5)
California
- Advanced Medical Research - La Palma
Florida
- Clinical Research of West Florida - Tampa
North Carolina
- Joint and Muscle Research Institute - Charlotte
Ohio
- Paramount Medical Research & Consulting - Middleburg Heights
Pennsylvania
- Clinical Research Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2031-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07438496
The ClinicalTrials.gov registry entry for NCT07438496 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 183-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (228% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07438496 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07438496 about?
NCT07438496 is a clinical study titled "A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus". The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs...
What is the current status of trial NCT07438496?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2026-03-05. Estimated completion is 2031-11-07.
What conditions does trial NCT07438496 study?
This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.
What interventions are being tested in trial NCT07438496?
The interventions under investigation include: Placebo (DRUG), Nipocalimab (DRUG), Standard of care treatment (DRUG).
Who is sponsoring clinical trial NCT07438496?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07438496 being conducted?
This trial has 5 study locations across California, Florida, North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Erythematosus, Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
RECRUITING · Phase 3
-
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
-
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.